Day One Biopharmaceuticals (DAWN) director exits all equity as Servier cash merger closes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Day One Biopharmaceuticals director Saira Ramasastry disposed of all reported equity interests in connection with the company’s cash merger with Servier. The filing shows 40,485 shares of Common Stock, 15,000 restricted stock units and multiple stock option grants were surrendered to the issuer on April 23, 2026.
Under the merger, each Day One share was purchased or converted into the right to receive $21.50 in cash, and each option or RSU was canceled for a cash payment based on this price, less any applicable exercise price and taxes. Following these transactions, the Form 4 lists no remaining shares or options for the reporting person.
Positive
- None.
Negative
- None.
Insights
All reported director equity is cashed out as part of the Servier acquisition.
The transactions reflect how outstanding equity is treated in a cash merger rather than discretionary trading. Common shares, RSUs, and options held by Saira Ramasastry were canceled and exchanged for cash tied to the $21.50 per-share merger price.
These are coded as dispositions to the issuer, not open-market sales, so they mainly document the equity conversion mechanics at closing. The filing shows no remaining options in the derivative summary and zero shares after the transactions, consistent with a full cash-out of the reported awards at the April 23, 2026 closing.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Ramasastry Saira
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy Common Stock) | 40,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 47,581 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 28,700 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 37,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 32,335 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 22,500 | $0.00 | -- |
| Disposition | Restricted Stock Unit (RSU) | 15,000 | $0.00 | -- |
| Disposition | Common Stock | 40,485 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 0 shares (Direct, null);
Restricted Stock Unit (RSU) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. The options are fully vested. Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan. RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Key Figures
Common shares disposed: 40,485 shares
RSUs disposed: 15,000 units
Option grant 1 shares: 22,500 options
+4 more
7 metrics
Common shares disposed
40,485 shares
Disposition to issuer on April 23, 2026
RSUs disposed
15,000 units
RSUs canceled for cash at merger closing
Option grant 1 shares
22,500 options
Stock options at $7.01 exercise price disposed
Option grant 2 shares
32,335 options
Stock options at $8.99 exercise price disposed
Additional option grants
139,781 options
Four further option lines at $8.99 exercise price disposed
Merger cash price
$21.50 per share
Offer Price and Merger Consideration for each common share
Dispose transactions
8 transactions
All coded as disposition to issuer on April 23, 2026
Key Terms
Agreement and Plan of Merger, Merger Consideration, Offer Price, Restricted Stock Unit (RSU), +2 more
6 terms
Agreement and Plan of Merger regulatory
"entered into an Agreement and Plan of Merger (the "Merger Agreement")."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
Offer Price financial
"purchased for $21.50 per share (the "Offer Price"), net to the seller in cash"
The offer price is the amount per share that a company or underwriter sets when selling new stock or bonds to investors, like the price tag on an item in a store. It matters because it determines how much investors must pay, shapes the initial market value of the security, and influences whether demand will be strong or weak — which affects early trading performance and potential returns.
Restricted Stock Unit (RSU) financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
deferred stock units financial
"the RSUs will automatically convert into an equal number of deferred stock units"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
unforeseeable emergency regulatory
"upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan."
FAQ
What did Day One Biopharmaceuticals (DAWN) director Saira Ramasastry report in this Form 4?
The Form 4 reports that director Saira Ramasastry disposed of all reported equity positions in Day One Biopharmaceuticals. Common shares, RSUs, and stock options were surrendered to the issuer in connection with the company’s cash merger with Servier, leaving no reported remaining holdings.
How were Day One Biopharmaceuticals (DAWN) RSUs and options treated in the Servier merger?
All outstanding RSUs and stock options became fully vested immediately before the merger, then were canceled at closing. Each RSU and option converted into a cash right based on the $21.50 per-share merger consideration, reduced by the relevant stock option exercise price and applicable withholding taxes.
Does the Form 4 show any remaining Day One Biopharmaceuticals (DAWN) holdings for the reporting person?
The Form 4 lists zero shares of common stock and zero derivative securities following the transactions. This indicates the reported common shares, RSUs, and stock options were fully cashed out or canceled for cash at the merger closing, with no remaining positions shown in this filing.
Are these DAWN Form 4 transactions open-market sales or part of the merger process?
The transactions are coded as "Disposition to issuer" and occurred at the merger closing. They represent equity being canceled or surrendered in exchange for cash merger consideration, rather than discretionary open-market sales initiated by the director on a stock exchange.